WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx's success, and we extend our deepest gratitude for his commitment and leadership. Effective immediately, Lynn O'Connor Vos will assume the role o

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec

ROCHESTER, Mich., Sept. 30, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced the appointment of Edward Stelmakh as chief financial officer (CFO) and chief operating officer (COO) effective October 11th, 2021. He succeeds Doug Baker within the financial organization, who will continue as executive vice president of finance and accounting. "Ed's extensive financial expertise, operational experience, and business analytics capabilities gained through years of leading the financial and operational teams of multiple growing public pharmaceutical companies

- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the third quarter of 2024 increased 30% to $21.3 million, as compared to $

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:   Date:Wednesday, November 13, 2024Time:4:30 p.m. Eastern Time (1:30

–   Q2 revenue of $18.8 million, increasing 36% year-over-year–   Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62%–   Won 8 DAAP deals during Q2 WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended June 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the second quarter of 2024 increased 36% to $18.8 million, as compared to $13.8 million in the same year ago period

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 8, 2024Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2024 increased 51% to $19.7 million, as compared to $13.0 million in the same year ago period.Gross profit

1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is providing a business update for 2024 and is preannouncing preliminary, unaudited results for select financials for the first quarter of 2024. For the first quarter, the Company expects r

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, March 28, 2024Time:8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Toll Free:1-877-423-9813International:1-201-689-8573Conference ID:13745113Call

- Increases guidance for 2023 and introduces guidance for 2024- Total revenue of $16.3 million- GAAP net loss per share of $(0.17)- Non-GAAP net income per share of $0.09- Total DAAP (fka RWD) deals for the year now stands at 16- Completed acquisition of Medicx Health after quarter end WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2023. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the thir

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has successfully completed its acquisition of Healthy Offers, Inc., dba Medicx Health ("Medicx"), a leading healthcare consumer-focused omnichannel marketing and analytics company. The two companies will operate independently through 2023 with full integration during the first quarter of 2024. The Company will hold a conference call on Monday, November 6, 2023, at 8:30 a.m. Eastern Time to discuss its results for the third qua

Preannounces Preliminary Third Quarter 2023 Results OptimizeRx adds new, proven, profitable technologies to become the most comprehensive healthcare marketing platform in the nation. Consolidated revenue run rate will increase to nearly $100 million and the acquisition is expected to be immediately accretive to earnings. Third quarter 2023 headline numbers to come in ahead of consensus with revenue for OptimizeRx standalone expected to be between $15.2-$15.5 million and non-GAAP net income expected to be $0.6-$1 million. Conference call to start at 8:30am EST on Thursday, October 12, 2023. WALTHAM, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OP

10-Q - OptimizeRx Corp (0001448431) (Filer)

8-K - OptimizeRx Corp (0001448431) (Filer)

10-Q - OptimizeRx Corp (0001448431) (Filer)

8-K - OptimizeRx Corp (0001448431) (Filer)

S-8 POS - OptimizeRx Corp (0001448431) (Filer)

S-8 - OptimizeRx Corp (0001448431) (Filer)

8-K - OptimizeRx Corp (0001448431) (Filer)

10-Q - OptimizeRx Corp (0001448431) (Filer)

8-K - OptimizeRx Corp (0001448431) (Filer)

8-K - OptimizeRx Corp (0001448431) (Filer)

B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

JMP Securities initiated coverage of OptimizeRx with a rating of Mkt Outperform and set a new price target of $15.00

Barclays initiated coverage of OptimizeRx with a rating of Equal Weight and set a new price target of $15.00

B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $30.00

Stifel initiated coverage of OptimizeRx with a rating of Buy and set a new price target of $19.00

SVB Leerink initiated coverage of OptimizeRx with a rating of Outperform and set a new price target of $38.00

Lake Street reiterated coverage of OptimizeRx with a rating of Buy and set a new price target of $76.00 from $98.00 previously

RBC Capital reiterated coverage of OptimizeRx with a rating of Outperform and set a new price target of $100.00 from $67.00 previously

B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $102.00

RBC Capital Mkts initiated coverage of OptimizeRx with a rating of Outperform and set a new price target of $65.00

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 price target.

7 analysts have shared their evaluations of OptimizeRx (NASDAQ:OPRX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 1 3 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.0, a high estimate of $17.00, and a low estimate of $13.00. Surpassing the previous average

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 price target.

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Wednesday. The Dow traded up 0.68% to 39,827.63 while the NASDAQ rose 1.29% to 16,723.91. The S&P 500 also rose, gaining, 1.03% to 5,300.57. Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Materials Stocks Delivering High-Dividend Yields Leading and Lagging SectorsUtilities shares rose by 1.5% on Wednesday. In trading on Wednesday, energy shares fell by 0.8%. Top Headline Shares of Arcos Dorados Holdings Inc. (NYSE:ARCO) fell around 5% on Wednesday after reporting results for its first quarter The company reported total revenues of $1.081 billion in the first quar

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $15 to $16.

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results. Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro. Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged

Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. Nutriband (NASDAQ:NTRB) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. Bone Biologics (NASDAQ:BBLG) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. OptimizeRx (NASDAQ:OPRX) shares moved upwards by 22.8% to $12.87. The market value of their

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday. The Dow traded up 0.59% to 39,790.88 while the NASDAQ rose 0.93% to 16,665.13. The S&P 500 also rose, gaining, 0.80% to 5,288.72. Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Materials Stocks Delivering High-Dividend Yields Leading and Lagging SectorsUtilities shares rose by 1.5% on Wednesday. In trading on Wednesday, energy shares fell by 0.8%. Top Headline U.S. retail sales came in unchanged month-over-month in April compared to a revised 0.6% increase in March. Equities Trading UP                        OptimizeRx Corporation (NAS

OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increase